Axogen: Positive Topline Results from Trial of Axoguard Nerve Cap

 REPOSE trial met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap^® vs. standard-of-care neurectomy at Month 12.

Axoguard Nerve Cap demonstrated statistical superiority vs. standard-of-care neurectomy in the reduction of total pain reported by participants over the course of follow-up.

Axogen, Inc.,  (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05).

Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05).

https://www.biospace.com/article/releases/axogen-inc-announces-positive-topline-results-from-repose-a-prospective-randomized-clinical-trial-of-axoguard-nerve-cap/